Podcast: Newly approved drug may slow progression of Alzheimer’s (Links to an external site)
Category: News
Lilly drug slows Alzheimer’s by 35%, bolstering treatment approach (Links to an external site)
Update on the DIAN-TU-001 Open Label Extension with Gantenerumab (Roche/Genentech)
Questions and concerns from sites and participants regarding the status of the DIAN-TU-001 gantenerumab open label extension (OLE) study and next steps in the study.
Conquering Alzheimer’s: a look at the therapies of the future (Links to an external site)
Seeking Alzheimer’s clues from few who escape genetic fate (Links to an external site)
Lifetime Achievement Award (Links to an external site)
Focused ultrasound technique leads to release of neurodegenerative disorders biomarkers (Links to an external site)
FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASE (Links to an external site)
Update on the DIAN-TU-001 Trial with E2814 and Lecanemab (Eisai Co., Ltd)
Response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for the treatment of symptomatic Alzheimer’s disease (AD)
Update on the DIAN-TU-002 Primary Prevention Trial
Update to the 15 November 2022 announcement by the Knight Family Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) regarding the DIAN-TU-002 Primary Prevention Trial with Gantenerumab.